Kisspeptin Dosage: How Much to Take, When & How

Kisspeptin Dosage: How Much to Take, When & How

Overview

Kisspeptin-10 is a neuropeptide that functions as a master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. It works by binding to the KISS1R receptor on GnRH neurons in the hypothalamus, triggering the release of gonadotropin-releasing hormone (GnRH), which subsequently stimulates luteinizing hormone (LH) and follicle-stimulating hormone (FSH) production. Unlike direct GnRH agonists, kisspeptin preserves physiological pulsatility, making it suitable for intermittent dosing protocols without significant desensitization risk.

Kisspeptin is available in two primary routes of administration: injection (subcutaneous or intramuscular) and intranasal spray. The peptide is primarily used in research contexts and increasingly in clinical settings for fertility support, hypogonadism evaluation, and recovery of suppressed HPG axis function following anabolic steroid use.

Disclaimer: This guide is educational information only and should not be considered medical advice. Kisspeptin is not approved as a therapeutic drug in most jurisdictions and exists in a regulatory gray area. Before using kisspeptin, consult with a qualified healthcare provider, particularly given regulatory and safety considerations.

Standard Dosing Protocol

Kisspeptin dosing varies significantly by route of administration and intended use. The following represents baseline research-supported dosing:

Injection (Subcutaneous or Intramuscular):

• Dose Range: 50–150 micrograms (mcg) per administration
• Frequency: Once daily or every other day
• Typical Starting Dose: 50–75 mcg
• Administration Time: Evening or morning, depending on personal response

Intranasal Administration:

• Dose Range: 1–3 milligrams (mg) per administration
• Frequency: Once daily
• Typical Starting Dose: 1 mg
• Administration Time: Morning or evening

The wide dose range exists because individual sensitivity varies considerably based on body weight, baseline HPG axis function, age, and prior hormonal status. Leaner individuals and those with suppressed baseline hormone levels typically require lower doses, while those with intact baseline function may tolerate higher doses.

Dosing by Goal

Kisspeptin's primary clinical application is HPG axis modulation. Dosing recommendations shift based on your specific objective:

For HPG Axis Restart (Post-Steroid Suppression or Hypogonadism):

• Injection: 75–100 mcg every other day
• Intranasal: 1.5–2 mg once daily
• Expected Timeline: 4–8 weeks to observe LH and FSH normalization
• Rationale: Moderate dosing stimulates endogenous hormone production without overwhelming the system, allowing gradual recovery of pulsatile signaling

For Fertility Optimization (Women):

• Intranasal: 1–2 mg once daily
• Injection: 50–75 mcg once daily
• Expected Timeline: 8–12 weeks; coordinate with medical monitoring
• Rationale: Lower, consistent dosing supports normal cyclicity and ovulation. Clinical data shows intranasal kisspeptin-54 induces significant LH increases (mean 4.4 ± 0.6 IU/L above baseline). Women require strict medical supervision due to ovarian hyperstimulation risk

For General Hormonal Support:

• Injection: 50 mcg every other day or 50–75 mcg once daily
• Intranasal: 1 mg once daily
• Expected Timeline: 4–6 weeks to assess effects
• Rationale: This conservative approach minimizes side effects while supporting baseline HPG function

For Joint Health & Anti-Inflammation (Emerging, Limited Evidence):

• Injection: 100–150 mcg every other day
• Intranasal: 2–3 mg once daily
• Note: This application is mechanistic only; human efficacy is not established. Kisspeptin-10 showed anti-senescence effects in chondrocytes in vitro at 50–100 nM concentrations, but translating this to dosing is speculative

How to Administer

Injection Administration:

1. Preparation: Use sterile syringes and inject into the subcutaneous fat of the abdomen, thigh, or upper arm. Some users rotate injection sites to minimize tissue irritation
2. Technique: Pinch the skin at the injection site, insert the needle at a 45–90-degree angle, and slowly inject the kisspeptin solution
3. Dosage Accuracy: Ensure your kisspeptin is dosed in solution form (typically 10 mg/mL or similar concentrations). Calculate the volume needed based on your target dose:
   • For 50 mcg from a 10 mg/mL solution: inject 0.005 mL (5 microliters)
   • For 100 mcg: inject 0.01 mL (10 microliters)
4. Timing: Inject in the evening if using daily dosing to align with natural testosterone rhythms, or choose a consistent time for every-other-day protocols
5. Post-Injection: Common side effects include transient flushing (30–60 minutes post-injection), mild injection site erythema, and occasionally mild nausea. These are temporary and typically resolve within 2 hours

Intranasal Administration:

1. Preparation: Use a nasal spray device or atomizer calibrated for peptide delivery (0.1 mL per spray typical)
2. Dosage Calculation: A 1 mg dose typically requires 0.1 mL (one spray) from a standard 10 mg/mL nasal formulation
3. Technique: Blow your nose gently to clear nasal passages. Tilt your head slightly back, insert the nozzle into one nostril, and spray while sniffing gently to distribute the peptide across nasal epithelium
4. Timing: Administer once daily, preferably in the morning to allow assessment of effects (mild flushing, warmth) during waking hours
5. Consistency: Use the intranasal route consistently; switching between routes mid-protocol can complicate dose-response assessment

Cycling & Timing

Unlike short-acting peptides, kisspeptin typically does not require aggressive cycling protocols due to its upstream mechanism of action (it stimulates GnRH release rather than replacing it). However, structured cycling improves long-term HPG axis health and minimizes adaptation:

Standard Cycling Protocol (Injection):

• 4 Weeks On / 2 Weeks Off: Dose at 50–100 mcg every other day for 4 weeks, then take 2 weeks off entirely. This allows pituitary and hypothalamic KISS1R receptors to remain sensitive
• Repeat: Continue this cycle for 12–16 weeks total (approximately 3–4 complete cycles)

Standard Cycling Protocol (Intranasal):

• 5 Weeks On / 1 Week Off: Use 1–2 mg daily for 5 weeks, take 1 week off, then resume. This is slightly more aggressive because intranasal delivery is less concentrated
• Repeat: Continue for 12–20 weeks total (3–4 cycles)

Timing Considerations:

• Time of Day: Morning or evening both work; choose based on when you prefer to assess side effects. If using daily dosing, consistency matters more than time of day
• Days of Week: Many users follow a Monday–Friday protocol with weekends off, which functionally resembles every-other-day dosing and simplifies adherence
• Coordination with Bloodwork: Plan baseline bloodwork (LH, FSH, testosterone, estradiol) before starting, then retest after 4 weeks to assess individual responsiveness. This guides dose adjustments

Post-Cycle Recovery: After completing a multi-cycle protocol (8–16 weeks on), take 3–4 weeks off. During this period, monitor whether HPG axis self-sustains or begins to decline, which indicates whether additional cycles are needed. Some users find that 1–2 cycles of kisspeptin are sufficient to reset the axis long-term; others require periodic re-dosing.

Beginner vs. Advanced Dosing

Beginner Protocol (Newly Starting):

• Dose: 50 mcg (injection) or 1 mg (intranasal)
• Frequency: Every other day (injection) or once daily (intranasal)
• Duration: 4 weeks assessment phase
• Cycle: 4 weeks on, 2 weeks off (injection) or 5 weeks on, 1 week off (intranasal)
• Monitoring: Track injection site reactions, flushing, libido changes, and mood. Obtain bloodwork at baseline and week 4
• Adjustment: If well-tolerated and HPG axis response is muted, increase dose to 75 mcg or 1.5 mg for cycles 2 and 3

Advanced Protocol (Experienced Users):

• Dose: 100–150 mcg (injection) or 2–3 mg (intranasal)
• Frequency: Once daily (injection) or once daily (intranasal)
• Duration: 6–8 week cycles
• Cycle: 6 weeks on, 2 weeks off (injection) or 8 weeks on, 2 weeks off (intranasal)
• Monitoring: Track detailed hormone panels (LH, FSH, testosterone, estradiol, prolactin) every 3 weeks. Assess sexual function, mood, energy, and recovery markers
• Adjustment: Response varies; some advanced users use split dosing (e.g., 50 mcg twice daily) to maintain more consistent stimulation, though this is less common in research protocols
• Stacking: Advanced users sometimes combine kisspeptin with GnRH agonists or HCG for synergistic HPG axis stimulation, but this should only occur under medical supervision

Common Dosing Mistakes

1. Underdosing Due to Fear of Side Effects Many users start too conservatively (25–30 mcg injection) because they fear flushing or warmth sensations. These side effects, while uncomfortable, are benign and resolve within 2 hours. Underdosing extends timelines unnecessarily. Minimum effective doses for HPG axis restart are 50 mcg (injection) or 1 mg (intranasal).

2. Over-Cycling Without Recovery Dosing continuously for 12+ weeks without breaks can lead to receptor desensitization, particularly with daily administration. Build in 1–2 week breaks every 4–6 weeks.

3. Inconsistent Administration Timing Switching between morning and evening dosing, or skipping doses unpredictably, confounds dose-response assessment. Choose a time and maintain it.

4. Incorrect Volume Calculation Users frequently miscalculate injection volumes, especially with peptides dosed in micrograms. Double-check your kisspeptin concentration (mg/mL) and calculate precisely:

• Formula: (Target dose in mcg / 1000) ÷ Concentration in mg/mL = Volume in mL

5. Ignoring Baseline Bloodwork Starting kisspeptin without baseline hormone levels makes it impossible to assess individual responsiveness or determine if the dose is working. Always obtain LH, FSH, and testosterone before starting.

6. Combining with Other HPG Modulators Recklessly Stacking kisspeptin with GnRH agonists, SARMs, or anabolic steroids without medical oversight can cause unpredictable pituitary response. If combining treatments, do so under professional guidance and increase monitoring frequency.

7. Using Intranasal Kisspeptin in a Nasal-Congested State Nasal congestion, allergies, or chronic sinusitis severely impairs intranasal peptide absorption. If your nasal passages are congested, use saline rinse first or delay dosing. Consider switching to injection if intranasal absorption is chronically compromised.

8. Neglecting Side Effect Tolerance Increased libido (sometimes uncomfortably intense), nausea at higher doses, or headaches indicate the dose is appropriate or slightly high. Don't escalate further if experiencing these; instead, reduce to the previous dose or extend cycle-off periods.

Cost Considerations

Kisspeptin typically costs $40–$120 per month depending on:

• Route: Intranasal is often slightly cheaper than injection due to lower bioavailability requirements
• Dose: Higher doses (100–150 mcg injection) approach the upper cost range
• Source: Research-grade vs. compounded pharmaceutical-grade sources; the latter is more expensive but often higher quality
• Frequency: Multi-cycle protocols (3–4 cycles spanning 12–16 weeks) cost approximately $120–$480 total for a complete reset protocol

Summary Dosing Table

Final Guidance

Kisspeptin dosing is highly individualized. Start conservatively, monitor bloodwork closely, and adjust doses based on objective hormone markers and subjective response. The 50–150 mcg injection range and 1–3 mg intranasal range accommodate most users, but your optimal dose depends on body composition, baseline HPG status, age, and objectives.

Maintain consistent dosing timing, plan breaks into your protocol, and prioritize medical supervision—particularly if female or using kisspeptin for fertility optimization. The favorable safety profile of kisspeptin in clinical trials makes it one of the safer HPG modulators available, but it remains a research chemical in most jurisdictions and should be treated with appropriate caution.